Bactiguard enters new therapeutic area through license agreement

Bactiguard and Vigilenz Medical Devices (Vigilenz), a Malaysian supplier of
medical and surgical products, have entered into a license agreement for
Bactiguard coated orthopaedic implants, covering the Asean region.
Bactiguard aims to expand its licensing business to new therapeutic areas and
Vigilenz’ ambition is to enhance its existing product range by introducing anti
-infective properties. Therefore, the companies have signed a license agreement
for Bactiguard coated orthopaedic trauma implant sets, covering the Asean
markets (Malaysia, Indonesia, Thailand, Philippines, Singapore, Brunei, Vietnam,
Myanmar, Cambodia & Laos).

“We are very excited about the partnership with Vigilenz as it expands our
licensing business to orthopaedic implants that will permanently remain in the
patient’s body. This new application will benefit from both the anti-infective
and tissue friendly properties of the Bactiguard coating”, says Christian Kinch,
CEO Bactiguard.

“By applying the Bactiguard coating to our surgical implants, we can prevent
hospital acquired infections and reduce the suffering for patients who are often
traumatized by accidents. I also see other potential future applications that
would benefit greatly from the Bactiguard coating”, says S. Choudhury, CEO
Vigilenz

The implants will initially be coated by Bactiguard. Vigilenz will be
responsible for the CE certification process and for conducting clinical trials.
As soon as the coated implants have been launched, Bactiguard will start
receiving royalties.

Several years ago, Bactiguard entered a strategic partnership and licensing
agreement with CR Bard, Inc (Bard) in the US. Since then, more than 140 million
Bactiguard coated Foley-catheters have been sold worldwide. Bactiguard’s
strategy is to expand the licensing business by adding new agreements to the
current successful agreement with Bard.

This is information that Bactiguard Holding AB (publ) is required to publish in
compliance with the Swedish Securities Market Act and/or the Financial
Instruments Trading Act. The information was submitted for publication on 11
November 2015, at 08.20.
För ytterligare information vänligen kontakta:
Cecilia Edström, Director of Sales & New business, mobile: 46 722 262 328
About Bactiguard
Bactiguard is a Swedish medtech company with a mission of preventing healthcare
associated infections, reducing the use of antibiotics and saving lives by
developing and supplying infection prevention solutions for the healthcare
industry. The company’s patented coating prevents healthcare associated
infections by reducing bacterial adhesion and growth on medical devices.
Bactiguard®-coated urinary catheters are market leading in the US and Japan, and
in recent years the company has developed its own product portfolio of catheters
for the urinary and respiratory tract and the blood stream. Bactiguard is
currently in a strong expansion phase, focused on new markets in the Europe,
Middle East, Asia, Latin America and Southern Africa. The company has market
presence in some 50 countries and has about 60 employees. Its headquarters is
located in Stockholm and production facilities in Sweden and Malaysia.
Bactiguard is listed on Nasdaq Stockholm. Read more about Bactiguard at
www.bactiguard.com